Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442113 | 0.84 | PDK2 (0.45) | MKNK1MKNK2GPR52ABL1 | |
| SCHEMBL4442762 | 0.81 | MKNK1 (0.66) | MKNK1MKNK2 | |
| SCHEMBL27261215 | 0.80 | MKNK1 (0.63) | CYP11B2CYP11B1MKNK1MKNK2GPR52 | |
| SCHEMBL4448921 | 0.80 | CHUK (0.58) | MKNK1MKNK2GPR52MAP4K4 | |
| SCHEMBL5105678 | 0.79 | MAP4K4 (0.43) | CYP11B2MKNK1MKNK2GPR52MAP4K4 | |
| SCHEMBL4443151 | 0.78 | GPR52 (0.45) | MKNK1MKNK2GPR52KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4439147 | 0.78 | CHUK (0.56) | MKNK1MKNK2GPR52MAP4K4 | |
| SCHEMBL4447717 | 0.78 | CYP11B2 (0.52) | CYP11B2CYP11B1 | |
| SCHEMBL5101905 | 0.77 | AAK1 (0.48) | CYP11B2MKNK1MKNK2GPR52MAP4K4 | |
| SCHEMBL30131558 | 0.76 | IKBKB (0.56) | MKNK2GPR52MAP4K4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | claimed |
| EP-2118062-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008084004-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | CMA1, ARSA, TPSAB1 | CYP11B2 2356/4885CYP11B1 2751/4885MKNK1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.